MindWalk (HYFT)
Market Price (5/30/2026): $1.77 | Market Cap: $82.3 MilSector: Health Care | Industry: Biotechnology
MindWalk (HYFT)
Market Price (5/30/2026): $1.77Market Cap: $82.3 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 96% | Weak multi-year price returns3Y Excs Rtn is -121% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -10 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -37% Stock price has recently run up significantly12M Rtn12 month market price return is 207% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -40%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -43% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19% High stock price volatilityVol 12M is 128% Key risksHYFT key risks include [1] its significant financial distress and unprofitability, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 96% |
| Weak multi-year price returns3Y Excs Rtn is -121% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -10 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -37% |
| Stock price has recently run up significantly12M Rtn12 month market price return is 207% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -40%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -43% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19% |
| High stock price volatilityVol 12M is 128% |
| Key risksHYFT key risks include [1] its significant financial distress and unprofitability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 5/22/2026
MindWalk (HYFT) stock has gained about 10% since 1/31/2026 because of the following key factors:
1. MindWalk Holdings Corp. reported significant revenue growth in its Q3 Fiscal 2026 financial results, with revenue increasing by 52% year-over-year to $4.2 million, marking the third consecutive quarter of year-over-year revenue gains. US revenue specifically doubled to $2.6 million, and the company maintained a cash position of $14.2 million as of January 31, 2026. This demonstrated financial improvement and operational strength contributed positively to the stock's movement.
2. The company announced key advancements in its AI-driven drug discovery platforms and pipeline during the period. In March 2026, MindWalk introduced its B Cell Llama™ nanobody discovery platform, which demonstrated multivalent VHH formats achieving sub-nanomolar potency and 10-25x activity over monovalent forms in a 2026 study. Furthermore, by May 2026, MindWalk revealed that over 20 drug candidates in partner pipelines originated from its antibody discovery work, with 10 programs actively progressing through Phase 1-3 clinical trials across oncology, immunology, neurology, and infectious disease.
Show more
MindWalk (HYFT) stock has gained about 10% since 1/31/2026 because of the following key factors:
1. MindWalk Holdings Corp. reported significant revenue growth in its Q3 Fiscal 2026 financial results, with revenue increasing by 52% year-over-year to $4.2 million, marking the third consecutive quarter of year-over-year revenue gains. US revenue specifically doubled to $2.6 million, and the company maintained a cash position of $14.2 million as of January 31, 2026. This demonstrated financial improvement and operational strength contributed positively to the stock's movement.
2. The company announced key advancements in its AI-driven drug discovery platforms and pipeline during the period. In March 2026, MindWalk introduced its B Cell Llama™ nanobody discovery platform, which demonstrated multivalent VHH formats achieving sub-nanomolar potency and 10-25x activity over monovalent forms in a 2026 study. Furthermore, by May 2026, MindWalk revealed that over 20 drug candidates in partner pipelines originated from its antibody discovery work, with 10 programs actively progressing through Phase 1-3 clinical trials across oncology, immunology, neurology, and infectious disease.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 8.6% change in HYFT stock from 1/31/2026 to 5/29/2026 was primarily driven by a 5.4% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 5292026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.62 | 1.76 | 8.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 27 | 28 | 5.4% |
| P/S Multiple | 2.8 | 2.9 | 3.9% |
| Shares Outstanding (Mil) | 46 | 47 | -0.8% |
| Cumulative Contribution | 8.6% |
Market Drivers
1/31/2026 to 5/29/2026| Return | Correlation | |
|---|---|---|
| HYFT | 8.6% | |
| Market (SPY) | 9.6% | 53.1% |
| Sector (XLV) | -3.0% | 20.9% |
Fundamental Drivers
The -5.9% change in HYFT stock from 10/31/2025 to 5/29/2026 was primarily driven by a -14.9% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5292026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.87 | 1.76 | -5.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 25 | 28 | 11.4% |
| P/S Multiple | 3.4 | 2.9 | -14.9% |
| Shares Outstanding (Mil) | 46 | 47 | -0.8% |
| Cumulative Contribution | -5.9% |
Market Drivers
10/31/2025 to 5/29/2026| Return | Correlation | |
|---|---|---|
| HYFT | -5.9% | |
| Market (SPY) | 11.5% | 43.3% |
| Sector (XLV) | 4.5% | 16.8% |
Fundamental Drivers
The 301.8% change in HYFT stock from 4/30/2025 to 5/29/2026 was primarily driven by a 190.5% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5292026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.44 | 1.76 | 301.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 14 | 28 | 95.9% |
| P/S Multiple | 1.0 | 2.9 | 190.5% |
| Shares Outstanding (Mil) | 33 | 47 | -29.4% |
| Cumulative Contribution | 301.8% |
Market Drivers
4/30/2025 to 5/29/2026| Return | Correlation | |
|---|---|---|
| HYFT | 301.8% | |
| Market (SPY) | 38.0% | 28.2% |
| Sector (XLV) | 8.3% | 9.6% |
Fundamental Drivers
The -31.5% change in HYFT stock from 4/30/2023 to 5/29/2026 was primarily driven by a -46.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302023 | 5292026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.57 | 1.76 | -31.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 20 | 28 | 38.5% |
| P/S Multiple | 3.2 | 2.9 | -7.8% |
| Shares Outstanding (Mil) | 25 | 47 | -46.4% |
| Cumulative Contribution | -31.5% |
Market Drivers
4/30/2023 to 5/29/2026| Return | Correlation | |
|---|---|---|
| HYFT | -31.5% | |
| Market (SPY) | 89.0% | 17.1% |
| Sector (XLV) | 17.7% | 7.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HYFT Return | -64% | -3% | -67% | -76% | 342% | -2% | -88% |
| Peers Return | -71% | -65% | 87% | -37% | -13% | 48% | -85% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| HYFT Win Rate | 33% | 67% | 25% | 25% | 75% | 40% | |
| Peers Win Rate | 17% | 33% | 56% | 36% | 42% | 67% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| HYFT Max Drawdown | -70% | -44% | -80% | -86% | -55% | -63% | |
| Peers Max Drawdown | -81% | -68% | -56% | -70% | -57% | -25% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TDOC, TALK, AMWL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/29/2026 (YTD)
How Low Can It Go
| Event | HYFT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -23.4% | -18.8% |
| % Gain to Breakeven | 30.6% | 23.1% |
| Time to Breakeven | 16 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -39.4% | -7.8% |
| % Gain to Breakeven | 65.0% | 8.5% |
| Time to Breakeven | 4 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -55.6% | -9.5% |
| % Gain to Breakeven | 125.2% | 10.5% |
| Time to Breakeven | 615 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -35.0% | -24.5% |
| % Gain to Breakeven | 53.8% | 32.4% |
| Time to Breakeven | 24 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -36.7% | -33.7% |
| % Gain to Breakeven | 57.9% | 50.9% |
| Time to Breakeven | 1 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -30.2% | -19.2% |
| % Gain to Breakeven | 43.3% | 23.8% |
| Time to Breakeven | 511 days | 105 days |
In The Past
MindWalk's stock fell -23.4% during the 2025 US Tariff Shock. Such a loss loss requires a 30.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | HYFT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -23.4% | -18.8% |
| % Gain to Breakeven | 30.6% | 23.1% |
| Time to Breakeven | 16 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -39.4% | -7.8% |
| % Gain to Breakeven | 65.0% | 8.5% |
| Time to Breakeven | 4 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -55.6% | -9.5% |
| % Gain to Breakeven | 125.2% | 10.5% |
| Time to Breakeven | 615 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -35.0% | -24.5% |
| % Gain to Breakeven | 53.8% | 32.4% |
| Time to Breakeven | 24 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -36.7% | -33.7% |
| % Gain to Breakeven | 57.9% | 50.9% |
| Time to Breakeven | 1 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -30.2% | -19.2% |
| % Gain to Breakeven | 43.3% | 23.8% |
| Time to Breakeven | 511 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -28.8% | -3.7% |
| % Gain to Breakeven | 40.5% | 3.9% |
| Time to Breakeven | 73 days | 6 days |
| 2013 Taper Tantrum | ||
| % Loss | -57.1% | -0.2% |
| % Gain to Breakeven | 133.3% | 0.2% |
| Time to Breakeven | 1161 days | 1 days |
In The Past
MindWalk's stock fell -23.4% during the 2025 US Tariff Shock. Such a loss loss requires a 30.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About MindWalk (HYFT)
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
AI Analysis | Feedback
nullAI Analysis | Feedback
- Antibodies: Offers a diverse range of antibodies for research applications.
- Enzymes & Assays: Provides enzymes and enzyme activity assays for various research needs.
- Specialized Proteins: Supplies proteins, deiminated proteins, and organoid growth factors for scientific research.
- Research Reagents: Delivers arthritis animal products and hybridoma products for research purposes.
Services:
- Antigen Services: Provides custom antigen modeling, design, and manufacturing.
- Antibody Discovery & Development: Offers comprehensive services including B cell sorting, phage display, multi-species antibody discovery, and manufacturing of various antibody types like bi-specific and VHH.
- Antibody Characterization & Engineering: Conducts antibody characterization on label-free biosensors and performs antibody engineering.
- Cell Line & Genetic Engineering: Specializes in DNA cloning, protein downstream processing, transient and stable cell line generation, and antibody optimization/humanization.
- Hybridoma Production: Manages hybridoma production with multiplexed, high-throughput screening and clone-picking.
- Cryopreservation: Provides services for the cryopreservation of biological materials.
AI Analysis | Feedback
ImmunoPrecise Antibodies Ltd. (HYFT) sells primarily to other companies and research organizations. Based on the provided description, the company engages in "research collaboration agreements" which indicate significant business relationships where ImmunoPrecise Antibodies provides its expertise, products, and services. Its major partners and collaborators mentioned are:- Pierre Fabre S.A.
- Elektrofi, Inc.
AI Analysis | Feedback
nullAI Analysis | Feedback
Jennifer Bath, PhD Chief Executive Officer and President
Dr. Jennifer Bath was appointed CEO of MindWalk in February 2018. She previously served as the Global Director of Client Relations at Aldevron, LLC. Dr. Bath founded and served as the Executive Director of the Concordia College Global Vaccine Institute. She also held a tenured position as an Associate Professor of Cellular and Molecular Biology at Concordia College for 15 years, and advised biotechnology and pharmaceutical companies on strategic and operational business practices. She holds a Ph.D. in Cellular and Molecular Biology from North Dakota State University.
R. Scott Areglado Chief Financial Officer
R. Scott Areglado was appointed Chief Financial Officer of MindWalk, effective October 20, 2025. He brings over 25 years of financial leadership experience across the healthcare, life sciences, and technology sectors. Most recently, he served as CFO of BrainsWay Ltd. from 2021 to 2023, where he helped redefine corporate strategy and led eight consecutive quarters of revenue growth. Prior to BrainsWay, he was the CFO at iCAD, Inc., a medical technology company specializing in AI-driven cancer detection, where he led multiple financings totaling over $50 million and supported several acquisitions. From 2005 to 2010, Mr. Areglado was Vice President and Controller at AMICAS, Inc., which was successfully acquired by Merge Healthcare. He holds an MBA from Babson College and a BBA in Accounting from the University of Massachusetts Amherst.
Thomas Lynch, PhD Chief Business Officer
Dr. Thomas Lynch was appointed Chief Business Officer of MindWalk, effective October 20, 2025. He possesses over two decades of experience at the intersection of biotechnology and software innovation. Dr. Lynch previously served as Director of Technical Sales & Scientific Support at Aldevron, where he built and led a global commercial team. As Vice President of Global Sales and Client Services at Aldevron, he spearheaded initiatives including the introduction of clinical mRNA manufacturing services and strategic account expansion, contributing to Aldevron's $9.6 billion acquisition by Danaher Life Sciences in 2021. Earlier in his career, he led global commercial operations at DNASTAR. Dr. Lynch earned his Ph.D. in Biochemistry at the University of Illinois and completed a postdoctoral fellowship funded by the National Cancer Institute at the University of Chicago. He currently serves on the Board of BioForward.
Dirk Van Hyfte, MD, PhD Chief Technology Officer
Dr. Dirk Van Hyfte is the Chief Technology Officer of MindWalk. He co-founded BioStrand, BioKey, and BioClue in 2019, serving as Co-Founder and CTO for BioStrand. BioStrand was later acquired by ImmunoPrecise Antibodies Ltd. in 2021, which subsequently rebranded as MindWalk Holdings Corp. Dr. Van Hyfte also co-founded iKnow in 1999, which was acquired by InterSystems in 2010. He holds patents for a revolutionary algorithm for genomic data analysis (at BioClue). He obtained his Ph.D. in Medical Artificial Intelligence from Radboud University in 2000 and a Doctor of Medicine - MD from KU Leuven in 1992. His early career included working as a Clinical Psychiatrist.
Ingrid Brands, MD, PhD Chief Innovation and Strategy Officer
Dr. Ingrid Brands is the Chief Innovation and Strategy Officer of MindWalk. She co-founded BioStrand in 2019, serving as its CEO, alongside Dirk Van Hyfte. BioStrand was acquired by ImmunoPrecise Antibodies Ltd. in 2021. Dr. Brands has over two decades of experience in management and senior research roles. She has pioneered innovative approaches in neuropsychological rehabilitation and held research positions at Libra Revalidatie & Audiologie and the Department of Rehabilitation at Erasmus University. She holds a Ph.D. in neurorehabilitation from the University of Maastricht and graduated Magna cum Laude in Medicine from the University of Leuven, specializing in Physical Medicine and Rehabilitation (PM&R).
AI Analysis | Feedback
MindWalk (symbol: HYFT), formerly known as ImmunoPrecise Antibodies Ltd., faces several key risks to its business. The company, which is transitioning into an AI-driven TechBio entity, relies heavily on its proprietary AI platforms for drug discovery. Here are the key risks to MindWalk:1. Persistent and Significant Net Losses and Funding Requirements
MindWalk (formerly ImmunoPrecise Antibodies Ltd.) has consistently reported substantial net losses, raising concerns about its path to profitability and its ongoing reliance on capital raises to fund operations. For the full fiscal year 2025, the company reported a net loss of $30.2 million CAD, an increase from the previous fiscal year's loss. This significant cash drain, coupled with a cash balance of $10.8 million CAD in FY2025, highlights considerable capital pressure that has necessitated equity raises and a transfer to the Nasdaq Capital Market.2. Rapid Obsolescence Risk in AI Drug Discovery and High Reliance on Proprietary Platforms
The company's future growth is intrinsically linked to the success and widespread adoption of its proprietary AI platforms, primarily LENSai™ and HYFT® technology. However, the AI drug discovery landscape is rapidly evolving, presenting a significant risk of rapid obsolescence for MindWalk's algorithms and data architecture. If competitors develop superior AI platforms or new foundational models emerge, MindWalk's current technology could become less competitive, posing a substantial threat to its revenue streams and market position. This reliance on a few key platforms creates a concentration risk.3. Execution Risks Related to Strategic Partnerships and Technology Development
MindWalk's strategy involves strategic partnerships and the continuous development and commercialization of its AI-based drug discovery tools. There are inherent execution risks associated with these partnerships, including potential delays or failures in developing and bringing new technologies to market. The successful realization of the company's growth hinges on effective execution in these areas, and any setbacks could materially impact its anticipated results and performance.AI Analysis | Feedback
nullAI Analysis | Feedback
ImmunoPrecise Antibodies Ltd., trading as MindWalk (NASDAQ: HYFT), operates in several significant addressable markets related to antibody production, drug discovery, and biologics services. The company has recently pivoted to a "Bio-Native AI platform business" model, leveraging its LENSai™ platform and HYFT® technology for accelerated drug discovery and development. While shifting focus, their services and products remain relevant to the broader markets of antibody discovery, custom antibodies, biologics contract development and manufacturing (CDMO), protein therapeutics, organoids, enzymes, and hybridoma technology. The addressable markets for MindWalk's main products and services are as follows: * **Antibody Discovery Market:** The global antibody discovery market was valued at approximately USD 9.06 billion in 2025 and is projected to reach around USD 22.28 billion by 2035, growing at a compound annual growth rate (CAGR) of 9.42% from 2026 to 2035. North America held the largest market share, capturing 36% in 2025. Another estimate places the global antibody discovery services market at USD 1.90 billion in 2025, projected to reach USD 3.54 billion in 2030, at a CAGR of 13.3%, with North America accounting for a 44.5% revenue share in 2024. * **Custom Antibody Market:** The global custom antibody market size was valued at USD 577.7 million in 2025 and is projected to grow to USD 1,303.4 million by 2034, exhibiting a CAGR of 9.61% during the forecast period. In 2025, North America dominated this market with a share of 51.79%. Another report indicates the global custom antibody market was approximately USD 501.47 million in 2023 and is estimated to grow at a CAGR of 10.3%. * **Biologics CDMO Market:** The global biologics contract development and manufacturing organization (CDMO) market size is estimated at USD 25.41 billion in 2025 and is projected to reach approximately USD 92.79 billion by 2034, expanding at a CAGR of 15.48% between 2025 and 2034. North America dominated the global biologics CDMO market, holding a 37% share in 2024. * **Protein Therapeutics Market:** The global protein therapeutics market size was valued at USD 375.3 billion in 2024 and is projected to reach around USD 740.07 billion by 2034, with a CAGR of 7.08% between 2025 and 2034. North America led this market in 2024. The U.S. market for protein therapeutics alone reached USD 130.45 billion in 2024 and is expected to rise to USD 206.89 billion by 2032. * **Organoids Market:** The global organoids market size was valued at USD 1.18 billion in 2025 and is projected to grow to USD 5.71 billion by 2034, exhibiting a CAGR of 18.8%. North America held the largest share of 41.52% in the global human organoids market in 2025. Another report for the combined organoids and spheroids market forecasts growth from USD 1.5 billion in 2026 to USD 9.77 billion by 2035, with a CAGR of 23.13%, and North America leading with 43% in 2025. * **Enzymes Market:** The global enzymes market size was estimated at USD 14.88 billion in 2024 and is projected to reach USD 25.15 billion by 2033, growing at a CAGR of 6.9% from 2026 to 2033. North America dominated the global enzymes market with a revenue share of 36.3% in 2025. * **Hybridoma Technology Market:** The global hybridoma technology market size is estimated at USD 2.5 billion in 2025, exhibiting a CAGR of 7% from 2025 to 2033. North America currently dominates this market with approximately 45% market share.AI Analysis | Feedback
MindWalk (symbol: HYFT) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends:
- Expansion of AI-Driven Drug Discovery and BioStrand Segment: MindWalk, a Bio-Native AI company, is heavily investing in and rebranding to emphasize its AI platform capabilities, particularly its proprietary LENSai™ technology. This platform aims to accelerate antibody discovery, development, and optimization by providing earlier insights, stronger candidate selection, and faster decision-making. The BioStrand segment, a core part of its AI initiatives, demonstrated exceptional growth of over 180% in Fiscal Year 2025 with high gross margins, indicating its strong contribution to revenue and profitability. The overall AI-based drug discovery market is projected to grow significantly, offering a favorable environment for MindWalk's specialized offerings.
- Strategic Partnerships and Collaborations: The company anticipates revenue generation from new strategic partnerships, including a significant USD $8–10 million oncology partnership focused on antibody-drug conjugates and bispecific antibodies. MindWalk emphasizes its strong partner momentum, with strategic collaborations expected to boost revenue streams and enhance operational efficiency.
- Transition to Software-as-a-Service (SaaS) Model for LensAI: MindWalk has begun transitioning its LensAI platform from a project-based revenue model to a Software-as-a-Service (SaaS) model, securing its first enterprise SaaS contract. This shift is expected to provide more predictable and recurring revenues, as well as attract new clients and facilitate margin expansion as existing clients adopt the subscription model.
- Advancement of Internal AI-Designed Therapeutic Pipeline: MindWalk is developing its own pipeline of AI-designed therapeutics, including a GLP-1 receptor agonist program and initiatives for universal dengue and influenza vaccines. The company's AI-designed GLP-1 peptides have shown promising results, and significant progress has been made in identifying key epitopes for universal vaccine candidates. To support these programs and attract targeted investment, MindWalk is establishing a segregated portfolio structure in the Cayman Islands for its AI-generated assets.
- Growth in Fee-for-Service Drug Discovery and Development: The company's traditional fee-for-service operations, particularly its Canadian business, have shown strong performance. Sales orders in Canada more than doubled in Q4 2025 compared to historical quarters, with a substantial increase in year-over-year sales and orders from new clients. This segment continues to be a consistent revenue generator, forming a key pillar of the company's growth strategy.
AI Analysis | Feedback
Share Repurchases
- MindWalk Holdings Corp. announced a share repurchase program on October 9, 2025.
- The program authorizes the repurchase of up to 2.3 million common shares, which represents approximately 5% of the company's outstanding shares.
- The repurchase program is effective from October 15, 2025, until October 15, 2026.
Share Issuance
- The number of outstanding shares for ImmunoPrecise Antibodies Ltd. (now MindWalk Holdings Corp.) significantly increased from 19.34 million in 2021 to 46.15 million in 2025.
- Specifically, shares outstanding grew by 64.06% from 28.13 million in 2024 to 46.15 million in 2025.
Outbound Investments
- MindWalk Holdings Corp. completed the sale of its Netherlands operations to AVS Bio, generating $11.7 million in net proceeds from the $12 million sale. This divestiture occurred around October 2025.
Capital Expenditures
- ImmunoPrecise Antibodies Ltd. (now MindWalk Holdings Corp.) reported Cash from Investing Activities of -1.1 million CAD as of October 31, 2025.
- The average annual growth rate for Cash from Investing Activities was 43% over the past three years and 15% over the past five years.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| MindWalk Stock Dropped 7.3% - Have You Assessed the Risk | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to HYFT.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 6.41 |
| Mkt Cap | 0.1 |
| Rev LTM | 238 |
| Op Inc LTM | -51 |
| FCF LTM | -9 |
| FCF 3Y Avg | -5 |
| CFO LTM | -3 |
| CFO 3Y Avg | -1 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.6% |
| Rev Chg 3Y Avg | 12.5% |
| Rev Chg Q | 7.9% |
| QoQ Delta Rev Chg LTM | 1.8% |
| Op Inc Chg LTM | 31.4% |
| Op Inc Chg 3Y Avg | 24.7% |
| Op Mgn LTM | -21.5% |
| Op Mgn 3Y Avg | -38.2% |
| QoQ Delta Op Mgn LTM | 1.1% |
| CFO/Rev LTM | -7.7% |
| CFO/Rev 3Y Avg | -16.4% |
| FCF/Rev LTM | -10.8% |
| FCF/Rev 3Y Avg | -20.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.1 |
| P/S | 1.8 |
| P/Op Inc | -4.9 |
| P/EBIT | -4.5 |
| P/E | -1.1 |
| P/CFO | -1.9 |
| Total Yield | -34.4% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -14.6% |
| D/E | 0.0 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 37.9% |
| 3M Rtn | 50.2% |
| 6M Rtn | 27.1% |
| 12M Rtn | 50.4% |
| 3Y Rtn | -53.8% |
| 1M Excs Rtn | 31.7% |
| 3M Excs Rtn | 40.0% |
| 6M Excs Rtn | 16.6% |
| 12M Excs Rtn | 29.4% |
| 3Y Excs Rtn | -136.1% |
Price Behavior
Price Behavior
| Market Price | $1.76 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 11/14/2008 | |
| Distance from 52W High | -45.0% | |
| 50 Days | 200 Days | |
| DMA Price | $1.27 | $1.68 |
| DMA Trend | down | up |
| Distance from DMA | 38.8% | 5.1% |
| 3M | 1YR | |
| Volatility | 94.4% | 128.4% |
| Downside Capture | 233.70 | 369.30 |
| Upside Capture | 313.62 | 393.55 |
| Correlation (SPY) | 46.4% | 32.6% |
HYFT Betas & Captures as of 4/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.62 | 2.78 | 3.45 | 3.02 | 2.80 | 1.22 |
| Up Beta | 3.16 | 2.77 | 3.20 | 2.45 | 2.02 | 0.84 |
| Down Beta | -2.55 | 3.51 | 2.54 | 2.39 | 2.31 | 1.14 |
| Up Capture | 261% | 275% | 297% | 443% | 1321% | 174% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 11 | 19 | 24 | 56 | 111 | 315 |
| Down Capture | 1364% | 262% | 359% | 252% | 191% | 111% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 8 | 20 | 35 | 62 | 132 | 409 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HYFT | |
|---|---|---|---|---|
| HYFT | 216.7% | 128.1% | 1.47 | - |
| Sector ETF (XLV) | 15.8% | 14.6% | 0.78 | 14.2% |
| Equity (SPY) | 30.3% | 11.8% | 1.94 | 32.3% |
| Gold (GLD) | 37.5% | 26.7% | 1.17 | 6.5% |
| Commodities (DBC) | 39.6% | 18.8% | 1.63 | -4.1% |
| Real Estate (VNQ) | 12.5% | 13.1% | 0.64 | 14.0% |
| Bitcoin (BTCUSD) | -31.8% | 41.6% | -0.81 | 19.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HYFT | |
|---|---|---|---|---|
| HYFT | -26.9% | 116.2% | 0.19 | - |
| Sector ETF (XLV) | 5.4% | 14.7% | 0.19 | 7.8% |
| Equity (SPY) | 14.3% | 17.0% | 0.66 | 14.1% |
| Gold (GLD) | 18.8% | 18.0% | 0.85 | 4.4% |
| Commodities (DBC) | 10.2% | 19.4% | 0.41 | 2.9% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 6.5% |
| Bitcoin (BTCUSD) | 14.6% | 54.6% | 0.46 | 7.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HYFT | |
|---|---|---|---|---|
| HYFT | -4.9% | 110.9% | 0.41 | - |
| Sector ETF (XLV) | 9.9% | 16.5% | 0.49 | 7.9% |
| Equity (SPY) | 15.9% | 17.9% | 0.76 | 12.4% |
| Gold (GLD) | 13.3% | 16.0% | 0.69 | 4.1% |
| Commodities (DBC) | 7.3% | 17.9% | 0.33 | 4.1% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.24 | 7.9% |
| Bitcoin (BTCUSD) | 67.0% | 66.9% | 1.06 | 6.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 5/29/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 01/31/2026 | 03/12/2026 | 6-K |
| 10/31/2025 | 12/15/2025 | 6-K |
| 07/31/2025 | 09/15/2025 | 6-K |
| 04/30/2025 | 07/29/2025 | 20-F |
| 01/31/2025 | 03/28/2025 | 6-K |
| 10/31/2024 | 12/10/2024 | 6-K |
| 07/31/2024 | 09/16/2024 | 6-K |
| 04/30/2024 | 07/29/2024 | 20-F |
| 01/31/2024 | 03/14/2024 | 6-K |
| 10/31/2023 | 12/14/2023 | 6-K |
| 07/31/2023 | 09/14/2023 | 6-K |
| 04/30/2023 | 07/10/2023 | 40-F |
| 01/31/2023 | 03/16/2023 | 6-K |
| 10/31/2022 | 12/15/2022 | 6-K |
| 07/31/2022 | 09/14/2022 | 6-K |
| 04/30/2022 | 07/29/2022 | 40-F |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 5/29/2026